Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Breast Cancer: A phase III randomized, double blind placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer which progressed on or after aromatase inhibitor treatment 5.2 Inclusion criteria Patients eligible for inclusion in this study have to meet all of the following criteria: 2. Patient has histologically and/or cytologically confirmed diagnosis of breast cancer 3. Patient has adequate tumor tissue (either archival tumor tissue or new tumor biopsy) for the analysis of PI3K-related biomarkers (PIK3CA mutation, PTEN expression). One tumor block (preferred) or a minimum of 20 unstained slides is recommended to determine the PI3K activation status. Enrollment in the study will be contingent to the central laboratory confirming reception of adequate amount of tissue including sufficient DNA for analysis. Note: Patients with previously documented PI3K pathway results by a Novartis designated laboratory and/or who have confirmation of adequate tumor tissue to perform all protocol required procedures (e.g. bridging study) are eligible. This may include patients who are being re-screened or coming from another Novartis study. 4. Patient has inoperable locally advanced or metastatic breast cancer 5. Patient has HER2 negative breast cancer (based on most recently analyzed biopsy) defined as a negative in situ hybridization by approved test or an IHC status of 0, 1+ or 2+ (if IHC 2+, a negative in situ hybridization test is required) by local laboratory testing 6. Patient has ER positive and/or PgR positive breast cancer by local laboratory testing (based on most recently analyzed biopsy) 7. Patient is postmenopausal. 8. Patient has disease refractory to AI defined as: Recurrence while on, or within 12 months of end of adjuvant treatment with AI, or Progression while on, or within one month of end of AI treatment for locally advanced or MBC Note: AI do not have to be the last treatment prior to enrollment in the run-in treatment phase. Patients who received maximum one prior chemotherapy line for MBC are allowed. Other prior anticancer therapies, e.g. tamoxifen are also allowed. Patients do not need to meet the definition of “refractory to AI” within any specified time period prior to enrollment in the run-in treatment phase. Patients can receive any number of endocrine/hormonal lines of therapy before or after meeting the definition of “refractory to AI”. 13. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 which the investigator believes is stable at the time of screening Pancreatic Cancer GAP Study: Phase II study of Gemcitabine and nab-Paclitaxel for Resectable Pancreas Cancer. The Australasian Gastro-Intestinal Trials Group (AGITG) Protocol No: AG0111PS 3.2 Inclusion criteria 1. Males or females with histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the pancreas. In those patients with histology or cytology highly suspicious for adenocarcinoma, the diagnosis of pancreatic adenocarcinoma will be made by integrating this histological data with the clinical and radiographic data (tumour mass visible on three phase CT scan (or MRI scan) of the pancreas). Patients with islet cell neoplasms are excluded; 2. Disease is clearly resectable on the basis of physical examination and the following objective CT criteria (or MRI if indicated): (i) no evidence of extra-pancreatic disease; (ii) no evidence of tumour abutment of the superior mesenteric artery (SMA) or coeliac axis (T4); and (iii) no evidence of portal vein infiltration of more than 180°of the circumference or occlusion of the superior mesenteric vein (SMV) or SMV–portal vein (PTV) confluence. 3. Age >18 yrs. 4. ECOG performance status 0 – 2, with a life expectancy of ≥ 3 months. 5. Adequate renal, hepatic and haematological function. Adequate hepatic function for this trial is defined as: a. Bilirubin <1.5 X ULN (Upper Limit of Normal), AST + ALT <3.0 X ULN. In patients who have had a recent biliary drainage and whose bilirubin is descending, a value of 3 X N (50 μmoles/L) is acceptable. Colorectal Cancer Assessment of Overall Survival of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with non-resectable liver metastases from primary colorectal carcinoma in a randomised clinical study Inclusion Criteria: Histologically confirmed adenocarcinoma of the colon or rectum, with or without primary tumour in situ. Unequivocal and measurable CT evidence of liver metastases which are not treatable by surgical resection or local ablation with curative intent at the time of study entry. Limited extra-hepatic metastases in the lung and/or lymph nodes are permitted. Metastases in the lung must either be not more than five nodules in number with no nodule more than 1 cm in diameter or one single lesion of up to 1.7 cm in diameter. Involvement of lymph nodes in one single anatomic region (pelvis, abdomen or chest) is permitted provided their longest diameter measures less than 2 cm. All imaging evidence used as part of the screening process must be within 28 days prior to the time of randomisation. Suitable for either treatment regimen and study procedures as determined by clinical assessment undertaken by the Investigator. Prior chemotherapy for metastatic colorectal cancer is not allowed. Patients may have received adjuvant chemotherapy or (neo-) adjuvant chemo-radiotherapy to the pelvis, provided the last dose of chemotherapy was administered at least 6 months prior to entry into this study. Radiotherapy to the pelvis is not an exclusion criterion. Melanoma BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma This multi-center, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in patients with completely resected, cutaneous BRAF-mutation positive melanoma at high risk for recurrence. Patients will be randomized to receive oral doses of vemurafenib 960 mg twice daily or matching placebo. The anticipated time on study treatment is 52 weeks. Inclusion Criteria: • Patients with completely resected, histologically confirmed, Stage IIC or Stage III, cutaneous melanoma where the BRAFV600 mutation status of the current primary tumor or involved lymph node is determined to be positive using the cobas® BRAF V600 Mutation Test. Patients with Stage IIIA disease must have at least one lymph node metastasis measuring > 1 mm in diameter • Patients must have been surgically rendered free of disease within 70 days of randomization • Eastern Cooperative Oncology Group performance status of 0 or 1 • Life expectancy of at least 5 years • Patients must have fully recovered from the effects of any major surgery or significant traumatic injury prior to the first dose of study treatment • Adequate hematologic, hepatic and renal function A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma Patients eligible for inclusion in this study have to meet all of the following criteria: 1. Signed written informed consent; 2. Male or female patient, age ≥ 18 years; 3. Histologically confirmed diagnosis of locally advanced, unresectable or metastatic cutaneous melanoma AJCC Stage IIIB, IIIC or IV (Appendix 1); 4. Presence of BRAF V600E or V600K mutation in tumor tissue prior to enrollment, as determined by a Novartis designated central laboratory(ies); 5. Naïve untreated patient for unresectable locally advanced or metastatic melanoma; Note: Prior adjuvant therapy is permitted (e.g. IFN, IL-2 therapy, any other immunotherapy or radiotherapy). 6. Evidence of at least one measurable lesion as detected by radiological or photographic methods according to Novartis guideline version 3.1 based on RECIST version 1.1; Note: A previously irradiated lesion is eligible to be considered as a measurable lesion provided that there is objective evidence of progression of the lesion since discontinuation of therapy and prior to starting study drug.